UNIFUZOL® is used in patients aged 18 years and older with obliterating atherosclerosis of the lower limb arteries. Its primary therapeutic benefit is achieved through its effect on peripheral vascular tone.

The medication improves microcirculation in areas of impaired blood flow by stimulating nitric oxide production and promoting capillary blood flow. UNIFUZOL® exhibits cardioprotective, anti-ischemic, mild diuretic, and antiplatelet effects.

It increases pain-free walking distance and maximum walking distance in patients with intermittent claudication.
Active pharmaceutical substance: arginine sodium succinate.